TrialClinical pharmacology in drug development2022

Pharmacokinetics, Safety, and Tolerability of NPC-21, an Anti-Cytomegalovirus Monoclonal Antibody, in Healthy Japanese and White Adult Men: A Randomized, Placebo-Controlled, First-in-Human Phase 1 Study.

Kenichi Furihata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.